chlorpromazine has been researched along with Polycystic Ovary Syndrome in 1 studies
Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.
chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.
Polycystic Ovary Syndrome: A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Santen, RJ | 1 |
| Bardin, CW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Reproductive Hormonal Alterations in Obesity, AIMS #1 & #2[NCT01457703] | 62 participants (Actual) | Interventional | 2010-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Follicle-stimulating hormone was measured hourly during the 12 hour study visit, and was compared between the obese and normal weight groups. (NCT01457703)
Timeframe: Measured hourly and averaged over the 12 hour study visit
| Intervention | IU/L (Mean) |
|---|---|
| BMI ≥30 kg/m2 | 3.8 |
| BMI 18-25 kg/m2 | 3.3 |
Follicle-stimulating hormone was measured hourly during the 12 hour study visit, and was compared between the obese and normal weight groups. (NCT01457703)
Timeframe: Measured hourly and averaged over the 12 hour study visit
| Intervention | IU/L (Mean) |
|---|---|
| BMI ≥30 kg/m2 | 5.31 |
| BMI 18-25 kg/m2 | 6.18 |
Luteinizing Hormone (LH) Pulse Amplitude was measured hourly during the 12 hour study visit, and was compared between the obese and normal weight groups. (NCT01457703)
Timeframe: Measured hourly and averaged over the 12 hour study visit
| Intervention | IU/L (Mean) |
|---|---|
| BMI ≥30 kg/m2 | 4.1 |
| BMI 18-25 kg/m2 | 3.6 |
Luteinizing Hormone (LH) Pulse Amplitude was measured hourly during the 12 hour study visit, and was compared between the obese and normal weight groups. (NCT01457703)
Timeframe: Measured hourly and averaged over the 12 hour study visit
| Intervention | IU/L (Mean) |
|---|---|
| BMI ≥30 kg/m2 | 2.21 |
| BMI 18-25 kg/m2 | 4.44 |
Pregnanediol glucuronide (PdG) was collected daily over the course of one menstrual cycle and averaged. (NCT01457703)
Timeframe: Averaged over the length of menstrual cycle
| Intervention | ug/cycle (Mean) |
|---|---|
| BMI ≥30 kg/m2 | 54.1 |
| BMI 18-25 kg/m2 | 88.7 |
1 other study available for chlorpromazine and Polycystic Ovary Syndrome
| Article | Year |
|---|---|
Episodic luteinizing hormone secretion in man. Pulse analysis, clinical interpretation, physiologic mechanisms.
Topics: Adult; Amenorrhea; Anorexia Nervosa; Chlorpromazine; Female; Follicle Stimulating Hormone; Half-Life | 1973 |